Patrick Wood
Stock Analyst at Morgan Stanley
(3.13)
# 1,247
Out of 5,090 analysts
117
Total ratings
51.11%
Success rate
1.24%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $136.51 | -1.11% | 3 | Dec 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $17 → $23 | $20.92 | +9.94% | 6 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $12.63 | -20.82% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $35.86 | +42.22% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $65.49 | +14.52% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $193.96 | +8.27% | 6 | Dec 2, 2025 | |
| BAX Baxter International | Maintains: Underweight | $19 → $15 | $18.54 | -19.09% | 6 | Dec 2, 2025 | |
| BLCO Bausch + Lomb | Upgrades: Overweight | $14 → $21 | $16.82 | +24.85% | 9 | Dec 2, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $74 → $80 | $85.46 | -6.39% | 8 | Oct 30, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $125 → $130 | $97.52 | +33.31% | 7 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $76 | $81.40 | -6.63% | 6 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $80.73 | -0.90% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $263.28 | +12.05% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $86.19 | -6.02% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $85.43 | +20.57% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $108.51 | -33.65% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $120.50 | +43.57% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $304.49 | +4.11% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $2.98 | +235.57% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $25.38 | +45.78% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $117.39 | - | 5 | Dec 11, 2017 |
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $136.51
Upside: -1.11%
Tandem Diabetes Care
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $17 → $23
Current: $20.92
Upside: +9.94%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $12.63
Upside: -20.82%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $35.86
Upside: +42.22%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $65.49
Upside: +14.52%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $193.96
Upside: +8.27%
Baxter International
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $18.54
Upside: -19.09%
Bausch + Lomb
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $16.82
Upside: +24.85%
GE HealthCare Technologies
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $74 → $80
Current: $85.46
Upside: -6.39%
Boston Scientific
Oct 23, 2025
Maintains: Overweight
Price Target: $125 → $130
Current: $97.52
Upside: +33.31%
Aug 28, 2025
Maintains: Equal-Weight
Price Target: $84 → $76
Current: $81.40
Upside: -6.63%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $80.73
Upside: -0.90%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $263.28
Upside: +12.05%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $86.19
Upside: -6.02%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $85.43
Upside: +20.57%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $108.51
Upside: -33.65%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $120.50
Upside: +43.57%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $304.49
Upside: +4.11%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $2.98
Upside: +235.57%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $25.38
Upside: +45.78%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $117.39
Upside: -